O	0	10	Inhibition	Inhibition	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	18	PDGF	PDGF	NN	B-NP
O	18	19	-	-	HYPH	B-NP
O	19	29	stimulated	stimulate	VBN	I-NP
O	30	33	and	and	CC	I-NP
B-Cellular_component	34	40	matrix	matrix	NN	I-NP
O	40	41	-	-	HYPH	O
O	41	49	mediated	mediate	VBN	B-NP
O	50	63	proliferation	proliferation	NN	I-NP
O	64	66	of	of	IN	B-PP
O	67	72	human	human	JJ	B-NP
B-Cell	73	81	vascular	vascular	JJ	I-NP
I-Cell	82	88	smooth	smooth	JJ	I-NP
I-Cell	89	95	muscle	muscle	NN	I-NP
I-Cell	96	101	cells	cell	NNS	I-NP
O	102	104	by	by	IN	B-PP
O	105	110	SPARC	SPARC	NN	B-NP
O	111	113	is	be	VBZ	B-VP
O	114	125	independent	independent	JJ	B-ADJP
O	126	128	of	of	IN	B-PP
O	129	136	changes	change	NNS	B-NP
O	137	139	in	in	IN	B-PP
B-Cell	140	144	cell	cell	NN	B-NP
O	145	150	shape	shape	NN	I-NP
O	151	153	or	or	CC	I-NP
O	154	160	cyclin	cyclin	NN	I-NP
O	160	161	-	-	HYPH	B-NP
O	161	170	dependent	dependent	JJ	I-NP
O	171	177	kinase	kinase	NN	I-NP
O	178	188	inhibitors	inhibitor	NNS	I-NP
O	188	189	.	.	.	O

O	190	202	Interactions	Interaction	NNS	B-NP
O	203	208	among	among	IN	B-PP
O	209	215	growth	growth	NN	B-NP
O	216	223	factors	factor	NNS	I-NP
O	223	224	,	,	,	O
B-Cell	225	230	cells	cell	NNS	B-NP
O	230	231	,	,	,	O
O	232	235	and	and	CC	O
B-Cellular_component	236	249	extracellular	extracellular	JJ	B-NP
I-Cellular_component	250	256	matrix	matrix	NN	I-NP
O	257	265	regulate	regulate	VBP	B-VP
O	266	279	proliferation	proliferation	NN	B-NP
O	280	286	during	during	IN	B-PP
O	287	293	normal	normal	JJ	B-NP
O	294	305	development	development	NN	I-NP
O	306	309	and	and	CC	B-PP
O	310	312	in	in	IN	B-PP
O	313	324	pathologies	pathology	NNS	B-NP
O	325	329	such	such	JJ	B-PP
O	330	332	as	as	IN	I-PP
O	333	348	atherosclerosis	atherosclerosis	NN	B-NP
O	348	349	.	.	.	O

O	350	355	SPARC	SPARC	NN	B-NP
O	356	357	(	(	(	O
O	357	365	secreted	secrete	VBN	B-VP
O	366	373	protein	protein	NN	B-NP
O	373	374	,	,	,	O
O	375	381	acidic	acidic	JJ	B-ADJP
O	381	382	,	,	,	O
O	383	386	and	and	CC	O
O	387	391	rich	rich	JJ	B-ADJP
O	392	394	in	in	IN	B-PP
O	395	403	cysteine	cysteine	NN	B-NP
O	403	404	)	)	)	O
O	405	407	is	be	VBZ	B-VP
O	408	409	a	a	DT	B-NP
B-Cellular_component	410	416	matrix	matrix	NN	I-NP
O	416	417	-	-	HYPH	B-NP
O	417	427	associated	associate	VBN	I-NP
O	428	440	glycoprotein	glycoprotein	NN	I-NP
O	441	445	that	that	WDT	B-NP
O	446	455	modulates	modulate	VBZ	B-VP
O	456	459	the	the	DT	B-NP
O	460	468	adhesion	adhesion	NN	I-NP
O	469	472	and	and	CC	I-NP
O	473	486	proliferation	proliferation	NN	I-NP
O	487	489	of	of	IN	B-PP
B-Cell	490	498	vascular	vascular	JJ	B-NP
I-Cell	499	504	cells	cell	NNS	I-NP
O	504	505	.	.	.	O

O	506	508	In	In	IN	B-PP
O	509	513	this	this	DT	B-NP
O	514	519	study	study	NN	I-NP
O	519	520	,	,	,	O
O	521	523	we	we	PRP	B-NP
O	524	535	demonstrate	demonstrate	VBP	B-VP
O	536	540	that	that	IN	B-SBAR
O	541	546	SPARC	SPARC	NN	B-NP
O	547	555	inhibits	inhibit	VBZ	B-VP
O	556	561	human	human	JJ	B-NP
B-Cell	562	570	arterial	arterial	JJ	I-NP
I-Cell	571	577	smooth	smooth	JJ	I-NP
I-Cell	578	584	muscle	muscle	NN	I-NP
I-Cell	585	589	cell	cell	NN	I-NP
O	590	603	proliferation	proliferation	NN	I-NP
O	604	614	stimulated	stimulate	VBN	B-VP
O	615	617	by	by	IN	B-PP
O	618	626	platelet	platelet	NN	B-NP
O	626	627	-	-	HYPH	O
O	627	634	derived	derive	VBN	B-NP
O	635	641	growth	growth	NN	I-NP
O	642	648	factor	factor	NN	I-NP
O	649	651	or	or	CC	B-PP
O	652	654	by	by	IN	B-PP
O	655	663	adhesion	adhesion	NN	B-NP
O	664	666	to	to	TO	B-PP
O	667	676	monomeric	monomeric	JJ	B-NP
O	677	681	type	type	NN	I-NP
O	682	683	I	I	CD	I-NP
O	684	692	collagen	collagen	NN	I-NP
O	692	693	.	.	.	O

O	694	701	Binding	Binding	NN	B-NP
O	702	709	studies	study	NNS	I-NP
O	710	714	with	with	IN	B-PP
O	715	720	SPARC	SPARC	NN	B-NP
O	721	724	and	and	CC	I-NP
O	725	730	SPARC	SPARC	NN	I-NP
O	731	739	peptides	peptide	NNS	I-NP
O	740	748	indicate	indicate	VBP	B-VP
O	749	757	specific	specific	JJ	B-NP
O	758	761	and	and	CC	I-NP
O	762	771	saturable	saturable	JJ	I-NP
O	772	783	interaction	interaction	NN	I-NP
O	784	788	with	with	IN	B-PP
B-Cell	789	795	smooth	smooth	JJ	B-NP
I-Cell	796	802	muscle	muscle	NN	I-NP
I-Cell	803	808	cells	cell	NNS	I-NP
O	809	813	that	that	WDT	B-NP
O	814	822	involves	involve	VBZ	B-VP
O	823	826	the	the	DT	B-NP
O	827	828	C	C	NN	I-NP
O	828	829	-	-	HYPH	B-NP
O	829	837	terminal	terminal	JJ	I-NP
O	838	841	Ca2	Ca2	NN	I-NP
O	841	842	+	+	SYM	B-NP
O	842	843	-	-	HYPH	B-PP
O	843	850	binding	bind	VBG	B-NP
O	851	857	region	region	NN	I-NP
O	858	860	of	of	IN	B-PP
O	861	864	the	the	DT	B-NP
O	865	872	protein	protein	NN	I-NP
O	872	873	.	.	.	O

O	874	876	We	We	PRP	B-NP
O	877	881	also	also	RB	B-ADVP
O	882	888	report	report	VBP	B-VP
O	889	893	that	that	IN	B-SBAR
O	894	899	SPARC	SPARC	NN	B-NP
O	900	907	arrests	arrest	VBZ	B-VP
O	908	917	monomeric	monomeric	JJ	B-NP
O	918	926	collagen	collagen	NN	I-NP
O	926	927	-	-	HYPH	O
O	927	936	supported	support	VBN	B-VP
B-Cell	937	943	smooth	smooth	JJ	B-NP
I-Cell	944	950	muscle	muscle	NN	I-NP
I-Cell	951	955	cell	cell	NN	I-NP
O	956	969	proliferation	proliferation	NN	I-NP
O	970	972	in	in	IN	B-PP
O	973	976	the	the	DT	B-NP
O	977	981	late	late	JJ	I-NP
O	982	984	G1	G1	NN	I-NP
O	984	985	-	-	HYPH	B-NP
O	985	990	phase	phase	NN	I-NP
O	991	993	of	of	IN	B-PP
O	994	997	the	the	DT	B-NP
B-Cell	998	1002	cell	cell	NN	I-NP
O	1003	1008	cycle	cycle	NN	I-NP
O	1009	1011	in	in	IN	B-PP
O	1012	1015	the	the	DT	B-NP
O	1016	1023	absence	absence	NN	I-NP
O	1024	1026	of	of	IN	B-PP
O	1027	1029	an	an	DT	B-NP
O	1030	1036	effect	effect	NN	I-NP
O	1037	1039	on	on	IN	B-PP
B-Cell	1040	1044	cell	cell	NN	B-NP
O	1045	1050	shape	shape	NN	I-NP
O	1051	1053	or	or	CC	B-PP
O	1054	1056	on	on	IN	B-PP
O	1057	1063	levels	level	NNS	B-NP
O	1064	1066	of	of	IN	B-PP
O	1067	1073	cyclin	cyclin	NN	B-NP
O	1073	1074	-	-	HYPH	B-NP
O	1074	1083	dependent	dependent	JJ	I-NP
O	1084	1090	kinase	kinase	NN	I-NP
O	1091	1101	inhibitors	inhibitor	NNS	I-NP
O	1101	1102	.	.	.	O

O	1103	1109	Cyclin	Cyclin	NN	B-NP
O	1109	1110	-	-	HYPH	O
O	1110	1119	dependent	dependent	JJ	B-NP
O	1120	1126	kinase	kinase	NN	I-NP
O	1126	1127	-	-	HYPH	O
O	1127	1128	2	2	CD	B-NP
O	1129	1137	activity	activity	NN	I-NP
O	1137	1138	,	,	,	O
O	1139	1143	p107	p107	NN	B-NP
O	1144	1147	and	and	CC	O
O	1148	1154	cyclin	cyclin	NN	B-NP
O	1155	1156	A	A	NN	I-NP
O	1157	1163	levels	level	NNS	I-NP
O	1163	1164	,	,	,	O
O	1165	1168	and	and	CC	O
O	1169	1183	retinoblastoma	retinoblastoma	NN	B-NP
O	1184	1191	protein	protein	NN	I-NP
O	1192	1207	phosphorylation	phosphorylation	NN	I-NP
O	1208	1211	are	be	VBP	B-VP
O	1212	1220	markedly	markedly	RB	I-VP
O	1221	1228	reduced	reduce	VBN	I-VP
O	1229	1231	in	in	IN	B-PP
O	1232	1240	response	response	NN	B-NP
O	1241	1243	to	to	TO	B-PP
O	1244	1247	the	the	DT	B-NP
O	1248	1256	addition	addition	NN	I-NP
O	1257	1259	of	of	IN	B-PP
O	1260	1269	exogenous	exogenous	JJ	B-NP
O	1270	1275	SPARC	SPARC	NN	I-NP
O	1276	1279	and	and	CC	O
O	1279	1280	/	/	SYM	B-NP
O	1280	1282	or	or	CC	O
O	1283	1291	peptides	peptide	NNS	B-NP
O	1292	1299	derived	derive	VBN	B-VP
O	1300	1304	from	from	IN	B-PP
O	1305	1313	specific	specific	JJ	B-NP
O	1314	1321	domains	domain	NNS	I-NP
O	1322	1324	of	of	IN	B-PP
O	1325	1330	SPARC	SPARC	NN	B-NP
O	1330	1331	.	.	.	O

O	1332	1336	Thus	Thus	RB	B-ADVP
O	1336	1337	,	,	,	O
O	1338	1343	SPARC	SPARC	NN	B-NP
O	1343	1344	,	,	,	O
O	1345	1355	previously	previously	RB	B-VP
O	1356	1369	characterized	characterize	VBN	I-VP
O	1370	1372	as	as	IN	B-PP
O	1373	1375	an	an	DT	B-NP
O	1376	1385	inhibitor	inhibitor	NN	I-NP
O	1386	1388	of	of	IN	B-PP
O	1389	1397	platelet	platelet	NN	B-NP
O	1397	1398	-	-	HYPH	O
O	1398	1405	derived	derive	VBN	B-NP
O	1406	1412	growth	growth	NN	I-NP
O	1413	1419	factor	factor	NN	I-NP
O	1420	1427	binding	bind	VBG	B-VP
O	1428	1430	to	to	TO	B-PP
O	1431	1434	its	its	PRP$	B-NP
O	1435	1443	receptor	receptor	NN	I-NP
O	1443	1444	,	,	,	O
O	1445	1449	also	also	RB	B-ADVP
O	1450	1461	antagonizes	antagonize	VBZ	B-VP
B-Cell	1462	1468	smooth	smooth	JJ	B-NP
I-Cell	1469	1475	muscle	muscle	NN	I-NP
I-Cell	1476	1480	cell	cell	NN	I-NP
O	1481	1494	proliferation	proliferation	NN	I-NP
O	1495	1503	mediated	mediate	VBN	B-VP
O	1504	1506	by	by	IN	B-PP
O	1507	1516	monomeric	monomeric	JJ	B-NP
O	1517	1525	collagen	collagen	NN	I-NP
O	1526	1528	at	at	IN	B-PP
O	1529	1532	the	the	DT	B-NP
O	1533	1538	level	level	NN	I-NP
O	1539	1541	of	of	IN	B-PP
O	1542	1548	cyclin	cyclin	NN	B-NP
O	1548	1549	-	-	HYPH	O
O	1549	1558	dependent	dependent	JJ	B-NP
O	1559	1565	kinase	kinase	NN	I-NP
O	1565	1566	-	-	HYPH	O
O	1566	1567	2	2	CD	B-NP
O	1568	1576	activity	activity	NN	I-NP
O	1576	1577	.	.	.	O

